- Home
- IXHL vs SNTI Comparison
IXHL vs SNTI Comparison
Compare IXHL & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IXHL
- SNTI
- Stock Information
- Founded
- IXHL 2001
- SNTI 2016
- Country
- IXHL Australia
- SNTI United States
- Employees
- IXHL N/A
- SNTI N/A
- Industry
- IXHL
- SNTI Biotechnology: Pharmaceutical Preparations
- Sector
- IXHL
- SNTI Health Care
- Exchange
- IXHL Nasdaq
- SNTI Nasdaq
- Market Cap
- IXHL 49.1M
- SNTI 53.6M
- IPO Year
- IXHL N/A
- SNTI N/A
- Fundamental
- Price
- IXHL $0.35
- SNTI $1.65
- Analyst Decision
- IXHL
- SNTI Strong Buy
- Analyst Count
- IXHL 0
- SNTI 3
- Target Price
- IXHL N/A
- SNTI $9.67
- AVG Volume (30 Days)
- IXHL 22.0M
- SNTI 89.8K
- Earning Date
- IXHL 11-14-2025
- SNTI 11-13-2025
- Dividend Yield
- IXHL N/A
- SNTI N/A
- EPS Growth
- IXHL N/A
- SNTI N/A
- EPS
- IXHL N/A
- SNTI N/A
- Revenue
- IXHL $12,000.00
- SNTI N/A
- Revenue This Year
- IXHL $1,188.37
- SNTI N/A
- Revenue Next Year
- IXHL N/A
- SNTI $150.00
- P/E Ratio
- IXHL N/A
- SNTI N/A
- Revenue Growth
- IXHL N/A
- SNTI N/A
- 52 Week Low
- IXHL $0.08
- SNTI $1.26
- 52 Week High
- IXHL $2.65
- SNTI $16.94
- Technical
- Relative Strength Index (RSI)
- IXHL 43.91
- SNTI 39.34
- Support Level
- IXHL $0.35
- SNTI $1.82
- Resistance Level
- IXHL $0.38
- SNTI $1.99
- Average True Range (ATR)
- IXHL 0.03
- SNTI 0.15
- MACD
- IXHL 0.01
- SNTI -0.05
- Stochastic Oscillator
- IXHL 19.41
- SNTI 0.00
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
About SNTI Senti Biosciences Inc.
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.